Dalpiciclib (SHR-6390) in combination with ET is also in phase III clinical trial (DAWNA-1, NCT03927456) for patients with HR+/HER2− BC [66] and in phase I/II trials for several BC subtypes in combination with ET, chemotherapy or immunotherapy [67]. Here, HR is linked to breast cancer.